Risk factors for hepatocellular carcinoma in the USA
The latest issue of the American Journal of Gastroenterology investigates population-attributable fractions of risk factors for hepatocellular carcinoma in the United States.
Risk factors for hepatocellular carcinoma include hepatitis B and C viruses (HBV, HCV), excessive alcohol consumption, rare genetic disorders and diabetes/obesity.
The population attributable fractions of these factors, however, have not been investigated in population-based studies in the United States.
Persons 68 years diagnosed with hepatocellular carcinoma between 1994 and 2007 were identified in the SEER-Medicare database.
Dr Tania Welzel and colleagues from Germany selected a 5% random sample of persons residing in SEER locations for comparison.
As anticipated, the risk of hepatocellular carcinoma was increased in relationship to each factor: hepatitis B and C viruses, alcohol-related disorders, rare metabolic disorders, and diabetes and/or obesity.
Population attributable fractions of all factors combined was 65%
American Journal of Gastroenterology
The doctors found that the population attributable fractions of all factors combined was 65%.
The population attributable fractions were highest among Asians, and lowest among black persons.
Among individual factors, diabetes/obesity had the greatest population attributable fractions, followed by alcohol-related disorders, hepatitis B and C viruses and rare genetic disorders.
While diabetes/obesity had the greatest population attributable fractions among both males and females, alcohol-related disorders had the second greatest population attributable fractions among males and hepatitis C viruses the second greatest among females.
Diabetes/obesity had the greatest population attributable fractions among whites and Hispanics, while hepatitis C viruses had the greatest population attributable fractions among Asians and blacks.
The second greatest population attributable fractions was alcohol-related disorders in whites, Hispanics and blacks and hepatitis B virus in Asians.
Dr Welzel's team concludes, "The dominant risk factors for hepatocellular carcinoma in the United States among persons 68 years differ by sex and race/ethnicity."
"Overall, eliminating diabetes/obesity could reduce the incidence of hepatocellular carcinoma more than the elimination of any other factor."
Am J Gastroenterol 2013: 108: 1314–1321
20 August 2013
This blog is all about current FDA approved drugs to treat the hepatitis C virus (HCV) with a focus on treating HCV according to genotype, using information extracted from peer-reviewed journals, liver meetings/conferences, and interactive learning activities.
Risk Of Developing Liver Cancer After HCV Treatment
- Home
- Newly Diagnosed With Hep C? Or Considering Treatment?
- All FDA Approved Drugs To Treat Hepatitis C
- Hepatitis C Genotypes and Treatment
- Mavyret (glecaprevir/pibrentasvir)
- Vosevi (Sofosbuvir/Velpatasvir/Voxilaprevir)
- Epclusa® (Sofosbuvir/Velpatasvir)
- Harvoni® (Ledipasvir/Sofosbuvir)
- VIEKIRA XR/VIEKIRA Pak
- Zepatier(Elbasvir/Grazoprevir)
- Cure - Achieving sustained virologic response (SVR) in hepatitis C
- HCV Liver Fibrosis
- FibroScan® Understanding The Results
- HCV Cirrhosis
- Staging Cirrhosis
- HCV Liver Cancer
- Risk Of Developing Liver Cancer After HCV Treatment
- Treating Elderly HCV Patients
- Fatty Liver Disease: NAFLD/NASH
- Current research articles on ailments that may be related to HCV
- Is There A Natural Way To Improve Liver Fibrosis?
- Can Food Or Herbs Interact With Conventional Medical Treatments?
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment